The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma

Hector Alvarez, Elizabeth A. Montgomery, Collins Karikari, Marcia Canto, Kerry B. Dunbar, Jean S. Wang, Georg Feldmann, Seung Mo Hong, Michael C. Haffner, Alan K. Meeker, Sacha J. Holland, Jiaxin Yu, Thilo J. Heckrodt, Jing Zhang, Pingyu Ding, Dane Goff, Rajinder Singh, Juan Carlos Roa, Arivusudar Marimuthu, Gregory J. RigginsJames R. Eshleman, Barry D. Nelkin, Akhilesh Pandey, Anirban Maitra

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Esophageal adenocarcinoma (EAC) arises in the backdrop of reflux-induced metaplastic phenomenon known as Barrett esophagus. The prognosis of advanced EAC is dismal, and there is an urgent need for identifying molecular targets for therapy. Serial Analysis of Gene Expression (SAGE) was performed on metachronous mucosal biopsies from a patient who underwent progression to EAC during endoscopic surveillance. SAGE confirmed significant upregulation of Axl "tags" during the multistep progression of Barrett esophagus to EAC. In a cohort of 92 surgically resected EACs, Axl overexpression was associated with shortened median survival on both univariate (p < 0.004) and multivariate (p < 0.036) analysis. Genetic knockdown of Axl receptor tyrosine kinase (RTK) function was enabled in two EAC lines (OE33 and JHEsoAd1) using lentiviral short hairpin RNA (shRNA). Genetic knockdown of Axl in EAC cell lines inhibited invasion, migration and in vivo engraftment, which was accompanied by downregulation in the activity of the Ral GTPase proteins (RalA and RalB). Restoration of Ral activation rescued the transformed phenotype of EAC cell lines, suggesting a novel effector mechanism for Axl in cancer cells. Pharmacological inhibition of Axl was enabled using a small molecule antagonist, R428 (Rigel Pharmaceuticals). Pharmacological inhibition of Axl with R428 in EAC cell lines significantly reduced anchorage-independent growth, invasion and migration. Blockade of Axl function abrogated phosphorylation of ERBB2 (Her-2/neu) at the Tyr877 residue, indicative of receptor crosstalk. Axl RTK is an adverse prognostic factor in EAC. The availability of small molecule inhibitors of Axl function provides a tractable strategy for molecular therapy of established EAC.

Original languageEnglish (US)
Pages (from-to)1009-1018
Number of pages10
JournalCancer Biology and Therapy
Volume10
Issue number10
DOIs
StatePublished - Nov 15 2010
Externally publishedYes

Fingerprint

Adenocarcinoma
Therapeutics
Barrett Esophagus
Cell Line
ral GTP-Binding Proteins
axl receptor tyrosine kinase
Pharmacology
Gene Expression
GTP Phosphohydrolases
Small Interfering RNA
Up-Regulation
Down-Regulation
Phosphorylation
Phenotype
Biopsy
Survival
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • Axl
  • Barrett esophagus
  • Ral GTP
  • SAGE

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Alvarez, H., Montgomery, E. A., Karikari, C., Canto, M., Dunbar, K. B., Wang, J. S., ... Maitra, A. (2010). The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biology and Therapy, 10(10), 1009-1018. https://doi.org/10.4161/cbt.10.10.13248

The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. / Alvarez, Hector; Montgomery, Elizabeth A.; Karikari, Collins; Canto, Marcia; Dunbar, Kerry B.; Wang, Jean S.; Feldmann, Georg; Hong, Seung Mo; Haffner, Michael C.; Meeker, Alan K.; Holland, Sacha J.; Yu, Jiaxin; Heckrodt, Thilo J.; Zhang, Jing; Ding, Pingyu; Goff, Dane; Singh, Rajinder; Roa, Juan Carlos; Marimuthu, Arivusudar; Riggins, Gregory J.; Eshleman, James R.; Nelkin, Barry D.; Pandey, Akhilesh; Maitra, Anirban.

In: Cancer Biology and Therapy, Vol. 10, No. 10, 15.11.2010, p. 1009-1018.

Research output: Contribution to journalArticle

Alvarez, H, Montgomery, EA, Karikari, C, Canto, M, Dunbar, KB, Wang, JS, Feldmann, G, Hong, SM, Haffner, MC, Meeker, AK, Holland, SJ, Yu, J, Heckrodt, TJ, Zhang, J, Ding, P, Goff, D, Singh, R, Roa, JC, Marimuthu, A, Riggins, GJ, Eshleman, JR, Nelkin, BD, Pandey, A & Maitra, A 2010, 'The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma', Cancer Biology and Therapy, vol. 10, no. 10, pp. 1009-1018. https://doi.org/10.4161/cbt.10.10.13248
Alvarez, Hector ; Montgomery, Elizabeth A. ; Karikari, Collins ; Canto, Marcia ; Dunbar, Kerry B. ; Wang, Jean S. ; Feldmann, Georg ; Hong, Seung Mo ; Haffner, Michael C. ; Meeker, Alan K. ; Holland, Sacha J. ; Yu, Jiaxin ; Heckrodt, Thilo J. ; Zhang, Jing ; Ding, Pingyu ; Goff, Dane ; Singh, Rajinder ; Roa, Juan Carlos ; Marimuthu, Arivusudar ; Riggins, Gregory J. ; Eshleman, James R. ; Nelkin, Barry D. ; Pandey, Akhilesh ; Maitra, Anirban. / The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. In: Cancer Biology and Therapy. 2010 ; Vol. 10, No. 10. pp. 1009-1018.
@article{b7340695f6464b0ab330886a0ef866d0,
title = "The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma",
abstract = "Esophageal adenocarcinoma (EAC) arises in the backdrop of reflux-induced metaplastic phenomenon known as Barrett esophagus. The prognosis of advanced EAC is dismal, and there is an urgent need for identifying molecular targets for therapy. Serial Analysis of Gene Expression (SAGE) was performed on metachronous mucosal biopsies from a patient who underwent progression to EAC during endoscopic surveillance. SAGE confirmed significant upregulation of Axl {"}tags{"} during the multistep progression of Barrett esophagus to EAC. In a cohort of 92 surgically resected EACs, Axl overexpression was associated with shortened median survival on both univariate (p < 0.004) and multivariate (p < 0.036) analysis. Genetic knockdown of Axl receptor tyrosine kinase (RTK) function was enabled in two EAC lines (OE33 and JHEsoAd1) using lentiviral short hairpin RNA (shRNA). Genetic knockdown of Axl in EAC cell lines inhibited invasion, migration and in vivo engraftment, which was accompanied by downregulation in the activity of the Ral GTPase proteins (RalA and RalB). Restoration of Ral activation rescued the transformed phenotype of EAC cell lines, suggesting a novel effector mechanism for Axl in cancer cells. Pharmacological inhibition of Axl was enabled using a small molecule antagonist, R428 (Rigel Pharmaceuticals). Pharmacological inhibition of Axl with R428 in EAC cell lines significantly reduced anchorage-independent growth, invasion and migration. Blockade of Axl function abrogated phosphorylation of ERBB2 (Her-2/neu) at the Tyr877 residue, indicative of receptor crosstalk. Axl RTK is an adverse prognostic factor in EAC. The availability of small molecule inhibitors of Axl function provides a tractable strategy for molecular therapy of established EAC.",
keywords = "Axl, Barrett esophagus, Ral GTP, SAGE",
author = "Hector Alvarez and Montgomery, {Elizabeth A.} and Collins Karikari and Marcia Canto and Dunbar, {Kerry B.} and Wang, {Jean S.} and Georg Feldmann and Hong, {Seung Mo} and Haffner, {Michael C.} and Meeker, {Alan K.} and Holland, {Sacha J.} and Jiaxin Yu and Heckrodt, {Thilo J.} and Jing Zhang and Pingyu Ding and Dane Goff and Rajinder Singh and Roa, {Juan Carlos} and Arivusudar Marimuthu and Riggins, {Gregory J.} and Eshleman, {James R.} and Nelkin, {Barry D.} and Akhilesh Pandey and Anirban Maitra",
year = "2010",
month = "11",
day = "15",
doi = "10.4161/cbt.10.10.13248",
language = "English (US)",
volume = "10",
pages = "1009--1018",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "10",

}

TY - JOUR

T1 - The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma

AU - Alvarez, Hector

AU - Montgomery, Elizabeth A.

AU - Karikari, Collins

AU - Canto, Marcia

AU - Dunbar, Kerry B.

AU - Wang, Jean S.

AU - Feldmann, Georg

AU - Hong, Seung Mo

AU - Haffner, Michael C.

AU - Meeker, Alan K.

AU - Holland, Sacha J.

AU - Yu, Jiaxin

AU - Heckrodt, Thilo J.

AU - Zhang, Jing

AU - Ding, Pingyu

AU - Goff, Dane

AU - Singh, Rajinder

AU - Roa, Juan Carlos

AU - Marimuthu, Arivusudar

AU - Riggins, Gregory J.

AU - Eshleman, James R.

AU - Nelkin, Barry D.

AU - Pandey, Akhilesh

AU - Maitra, Anirban

PY - 2010/11/15

Y1 - 2010/11/15

N2 - Esophageal adenocarcinoma (EAC) arises in the backdrop of reflux-induced metaplastic phenomenon known as Barrett esophagus. The prognosis of advanced EAC is dismal, and there is an urgent need for identifying molecular targets for therapy. Serial Analysis of Gene Expression (SAGE) was performed on metachronous mucosal biopsies from a patient who underwent progression to EAC during endoscopic surveillance. SAGE confirmed significant upregulation of Axl "tags" during the multistep progression of Barrett esophagus to EAC. In a cohort of 92 surgically resected EACs, Axl overexpression was associated with shortened median survival on both univariate (p < 0.004) and multivariate (p < 0.036) analysis. Genetic knockdown of Axl receptor tyrosine kinase (RTK) function was enabled in two EAC lines (OE33 and JHEsoAd1) using lentiviral short hairpin RNA (shRNA). Genetic knockdown of Axl in EAC cell lines inhibited invasion, migration and in vivo engraftment, which was accompanied by downregulation in the activity of the Ral GTPase proteins (RalA and RalB). Restoration of Ral activation rescued the transformed phenotype of EAC cell lines, suggesting a novel effector mechanism for Axl in cancer cells. Pharmacological inhibition of Axl was enabled using a small molecule antagonist, R428 (Rigel Pharmaceuticals). Pharmacological inhibition of Axl with R428 in EAC cell lines significantly reduced anchorage-independent growth, invasion and migration. Blockade of Axl function abrogated phosphorylation of ERBB2 (Her-2/neu) at the Tyr877 residue, indicative of receptor crosstalk. Axl RTK is an adverse prognostic factor in EAC. The availability of small molecule inhibitors of Axl function provides a tractable strategy for molecular therapy of established EAC.

AB - Esophageal adenocarcinoma (EAC) arises in the backdrop of reflux-induced metaplastic phenomenon known as Barrett esophagus. The prognosis of advanced EAC is dismal, and there is an urgent need for identifying molecular targets for therapy. Serial Analysis of Gene Expression (SAGE) was performed on metachronous mucosal biopsies from a patient who underwent progression to EAC during endoscopic surveillance. SAGE confirmed significant upregulation of Axl "tags" during the multistep progression of Barrett esophagus to EAC. In a cohort of 92 surgically resected EACs, Axl overexpression was associated with shortened median survival on both univariate (p < 0.004) and multivariate (p < 0.036) analysis. Genetic knockdown of Axl receptor tyrosine kinase (RTK) function was enabled in two EAC lines (OE33 and JHEsoAd1) using lentiviral short hairpin RNA (shRNA). Genetic knockdown of Axl in EAC cell lines inhibited invasion, migration and in vivo engraftment, which was accompanied by downregulation in the activity of the Ral GTPase proteins (RalA and RalB). Restoration of Ral activation rescued the transformed phenotype of EAC cell lines, suggesting a novel effector mechanism for Axl in cancer cells. Pharmacological inhibition of Axl was enabled using a small molecule antagonist, R428 (Rigel Pharmaceuticals). Pharmacological inhibition of Axl with R428 in EAC cell lines significantly reduced anchorage-independent growth, invasion and migration. Blockade of Axl function abrogated phosphorylation of ERBB2 (Her-2/neu) at the Tyr877 residue, indicative of receptor crosstalk. Axl RTK is an adverse prognostic factor in EAC. The availability of small molecule inhibitors of Axl function provides a tractable strategy for molecular therapy of established EAC.

KW - Axl

KW - Barrett esophagus

KW - Ral GTP

KW - SAGE

UR - http://www.scopus.com/inward/record.url?scp=78549245919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78549245919&partnerID=8YFLogxK

U2 - 10.4161/cbt.10.10.13248

DO - 10.4161/cbt.10.10.13248

M3 - Article

C2 - 20818175

AN - SCOPUS:78549245919

VL - 10

SP - 1009

EP - 1018

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 10

ER -